Browse the evidence

GLP-1 receptor agonists or co-agonists have demonstrated substantial and sustained weight loss along with notable improvements in cardiometabolic markers.

Practitioners may consider GLP-1 receptor agonists as effective options for weight management and improving cardiometabolic health.

Endoscopic sleeve gastroplasty (ESG) has demonstrated durable weight loss, favorable safety, and superior cost-effectiveness compared to pharmacotherapy alone.

Practitioners may consider ESG as a viable option for patients seeking effective weight loss.

Combination strategies using endoscopic bariatric therapies (EBTs) and anti-obesity medications (AOMs) result in greater total-body weight loss than either modality alone.

Combining EBTs with AOMs may enhance weight loss outcomes for patients.

Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c.

Practitioners can consider semaglutide as an effective treatment for reducing BMI and improving glycemic control in obese T2DM patients.

Exercise is one of the most effective strategies to prevent sarcopenia.

Incorporating exercise into daily routines can significantly help in preventing muscle loss in older adults.

A combination of adequate nutrition and regular exercise is recommended to promote muscle health and function.

Practitioners should encourage both dietary and exercise interventions for optimal muscle health in older adults.

The management of MASLD in patients with T2D includes dietary and behavioral management, pharmacological treatment, and bariatric procedures.

Practitioners should consider a comprehensive management approach for diabetic patients with MASLD.

Patient-delivered lifestyle intervention yielded significantly less weight regain than standard-of-care (SOC) at month 18 (0.77 kg vs 2.37 kg; P = .002).

Patient-delivered interventions may be a viable alternative for weight loss maintenance.

Patient-delivered intervention showed parallel improvements in diastolic blood pressure, heart rate, physical activity, and sedentary behavior compared to SOC.

Improving cardiovascular metrics can enhance overall health in weight maintenance programs.

Both intermittent fasting (IF) and ketogenic diet (KD) independently show clinically significant benefits in improving metabolic parameters in metabolic syndrome (MetS) and type 2 diabetes (T2D), including reductions in HbA1c, fasting glucose, body weight, and triglycerides.

Practitioners may consider IF and KD as effective dietary interventions for managing MetS and T2D.

Use of GLP‐1 or GLP‐1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c.

Practitioners can consider GLP-1 and GLP-1/GIP RA therapies for weight management and glycemic control in lung transplant patients.

Semaglutide led to a mean relative weight loss of 13.3 ± 11.3% after 12 months in adults with type 1 diabetes.

Practitioners can consider semaglutide as an effective option for weight management in overweight/obese patients with type 1 diabetes.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) decreased from 82.6% to 30.4% after treatment with semaglutide.

Semaglutide may significantly improve liver health in patients with type 1 diabetes and MASLD.

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Lifestyle intervention combined with older obesity medications is associated with approximately 5%-10% weight loss.

Combining lifestyle changes with medications can enhance weight loss outcomes for patients.

GLP-1 analogs have shown efficacy in improving weight loss and cardiovascular risk factors.

Practitioners may consider GLP-1 analogs as a treatment option for weight management in menopausal women.

Initiation of semaglutide was significantly associated with a -3.8% reduction in weight at 13 to 24 months.

Semaglutide may be an effective option for weight management in adults.

Patients can achieve significant weight reduction with the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) compared with placebo when combined with a reduced-calorie diet and increased physical activity.

Practitioners should consider prescribing NB-ER for patients with obesity who are also engaging in dietary and physical activity changes.

The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual.

Practitioners should assess individual patient characteristics when prescribing NB-ER.

Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.

Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.

Lifestyle modification can provide glycemic benefits to prevent type 2 diabetes (T2D) and its comorbidities.

Practitioners should encourage lifestyle modifications as a standard approach to prevent T2D.

Adopting MLCDs, particularly those with sufficient fiber content, can reduce the risk of cardiovascular diseases in patients suffering from dyslipidemia.

Practitioners may consider recommending MLCDs with sufficient fiber to patients with dyslipidemia to help reduce cardiovascular risks.

Soy isoflavones can significantly contribute to lowering metabolic risk and affect hormonal balance in women with PCOS.

Incorporating soy isoflavones may be beneficial for women with PCOS in managing metabolic and hormonal issues.

The Mediterranean diet is advised for cardiovascular prevention in patients with familial hypercholesterolemia (FH).

Practitioners should consider recommending the Mediterranean diet to patients with FH.